Targeting Vascular Destruction by Sonosensitizer‐Free Sonocatalytic Nanomissiles Instigates Thrombus Aggregation and Nutrition Deprivation to Starve Pancreatic Cancer

Advanced Functional Materials, Год журнала: 2024, Номер 34(30)

Опубликована: Март 22, 2024

Abstract Sonosensitizers in current sonodynamic therapy (SDT) often suffer from poor delivery efficiency, phototoxicity, and disputed safety. To overcome these issues, a sonosensitizers‐free sonocatalytic nanomissile is constructed, wherein PLGA nanoparticles as vehicles conjugate with L‐arginine (LA) aptamer XQ2d capable of adsorbing CO 2 targeting CD71‐overexpressed pancreatic cancer, respectively. The adsorbed can respond to acidic tumor microenvironment local ultrasound release bubbles enhance ultrasound‐triggered inertial cavitation, which further split H O activate dissolved produce ·OH 1 , respectively, unlocking the ROS birth. Moreover, such bubbles‐enhanced cavitation also target intratumoral vascular destruction, instigate thrombus aggregation, induce nutrition oxygen deprivation, pose hypoxia alter metabolism, thus establishing an destruction‐targeted starvation therapy. strategy different previous presence undamaged blood vessels compromises their outcomes. Especially, active allows more sonosensitizer‐free nanomissiles retain significantly magnifying against subcutaneous orthotopic cancers. Therefore, research provides promising route therapeutic platform for clinical cancer

Язык: Английский

---

Construction of feature selection and efficacy prediction model for transformation therapy of locally advanced pancreatic cancer based on CT, 18F-FDG PET/CT, DNA mutation, and CA199

Cancer Cell International, Год журнала: 2025, Номер 25(1)

Опубликована: Янв. 19, 2025

Immunotherapy and radiotherapy play crucial roles in the transformation therapy of locally advanced pancreatic cancer; however, exploration effective predictive biomarkers has been unsatisfactory. With rapid development radiomics, next-generation sequencing, machine learning, there is hope to identify that can predict efficacy transformative treatment for cancer through simple non-invasive clinical methods. Our study focuses on using computed tomography (CT), positron emission tomography/computed (PET/CT), gene mutations, baseline carbohydrate antigen 199 (CA199) predicting treatment. We retrospectively collected data from 70 patients with who had undergone a biopsy pathological diagnosis. These complete enhanced CT images CA199 results. Among them, 65 evaluation results after 4 cycles, 54 PET/CT images, 51 DNA mutation detection results, 34 both Additionally, 47 available at baseline, 2 cycles. extracted radiomic features original lesion-enhanced (including subsequent follow-up scans), 18F-fluoro-2-deoxy-2-D-glucose (18F-FDG) PET, patient-specific related abdominal visceral fat. used short-term long-term as prediction outcomes performed statistical learning-based feature selection COX regression analysis potentially features. Subsequently, we separately or combination modeled features, PET CA199, construct models. Finally, investigated mixed effects model dynamic changes cycles efficacy. found including F1_ gray level co-occurrence matrix (GLCM), F2_gray run length (GLRLM), F5_neighboring tone difference (NGTDM), F6_Shape, such adipose tissue (VAT), tumor-to-liver ratio (T/L), standardized uptake value mean (SUVmean), GLCM, well be Baseline IntensityDirect, Shape, are independent factors In constructing model, ensemble learning methods adaptive boosting (AdaBoost), extreme gradient (XGBoost), RandomForest best. However, terms interpretability, decision tree provide most intuitive display details model. For time series patients' CT, long memory (LSTM) modeling yielded better A multimodal cancer. Various fusion approaches contribute guiding personalized precise

Язык: Английский

---

Case report: A successful case of targeted immunotherapy for locally advanced pancreatic cancer under non-surgical conditions

Frontiers in Immunology, Год журнала: 2025, Номер 15

Опубликована: Янв. 10, 2025

Locally advanced pancreatic cancer (LAPC) is a borderline unresectable malignancy that presents significant treatment challenges. The management of LAPC remains complex issue, particularly in patients who are not eligible for surgical resection. Here, we report the case 60-year-old woman diagnosed with through pathological biopsy subsequently underwent targeted immunotherapy following failure gemcitabine, oxaliplatin, and S-1 (G&S) chemotherapy regimen. Based on next-generation sequencing (NGS), patient's regimen was adjusted to include albumin-bound paclitaxel capecitabine chemotherapy, along PD-1 inhibitor camrelizumab (200 mg/cycle) six cycles. Throughout period, patient consistently declined intervention. Imaging studies, including an upper abdominal computed tomography (CT), revealed formation calcified layer surrounding cancerous tissue head. Remarkably, has shown stable disease no evidence metastasis since initiation immunotherapy. This highlights potential LAPC, non-surgical patients. A personalized approach guided by NGS, combined immunotherapy, effective alternative traditional strategies managing this challenging malignancy.

Язык: Английский

---

Neoadjuvant Immunotherapy for Localized Pancreatic Cancer: Challenges and Early Results

Cancers, Год журнала: 2023, Номер 15(15), С. 3967 - 3967

Опубликована: Авг. 4, 2023

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease due to its late presentation and tendency recur early even after optimal surgical resection. Currently, there are limited options for effective systemic therapy. In addition, PDAC typically generates an immune-suppressive tumor microenvironment; trials of immunotherapy in metastatic have yielded disappointing results. There considerable interest using approaches the neoadjuvant setting order prime immune system detect prevent micrometastatic recurrence. A scoping review was conducted identify published ongoing utilizing preoperative immunotherapy. total, 9 27 were identified. The included checkpoint inhibitors, cancer vaccines, other immune-modulating agents that target mechanisms distinct from inhibition. Most these phase which suggest improvements disease-free overall survival when combined with standard Ongoing exploring various combinations each chemotherapy and/or radiation. Rational combination addition therapy has potential improve outcomes PDAC, but further clinical needed, particularly those utilize adaptive trial design.

Язык: Английский

---

Evidence and Future Perspectives for Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Scoping Review

Cancers, Год журнала: 2024, Номер 16(9), С. 1632 - 1632

Опубликована: Апрель 24, 2024

Pancreatic cancer (PC) is a lethal disease that requires innovative therapeutic approaches to enhance the survival outcomes. Neoadjuvant treatment (NAT) has gained attention for resectable and borderline PC, offering improved resection rates enabling early intervention patient selection. Several retrospective studies have validated its efficacy. However, previous lacked intention-to-treat analyses appropriate resectability classifications. Randomized comparative trials may help clinical applicability of evidence. Therefore, after searching MEDLINE database, this scoping review presents comprehensive summary evidence from published (n = 14) ongoing 12) randomized Phase II III trials. Diverse regimens their outcomes were explored both PC. While some supported efficacy NAT, others demonstrated no clear benefits patients with The utility NAT been confirmed in but optimal remain debatable. Ongoing are investigating novel regimens, including immunotherapy, thereby highlighting dynamic landscape PC treatment. Studies should focus on biomarker identification, which enable precision oncology. Future endeavors aim refine strategies, guided by

Язык: Английский

---

Physiochemically and Genetically Engineered Bacteria: Instructive Design Principles and Diverse Applications

Advanced Science, Год журнала: 2024, Номер 11(30)

Опубликована: Июнь 12, 2024

With the comprehensive understanding of microorganisms and rapid advances physiochemical engineering bioengineering technologies, scientists are advancing rationally-engineered bacteria as emerging drugs for treating various diseases in clinical disease management. Engineered specifically refer to advanced or genetic technologies combination with cutting edge nanotechnology physical which have been validated play significant roles lysing tumors, regulating immunity, influencing metabolic pathways, etc. However, there has no specific reviews that concurrently cover physiochemically- genetically-engineered their derivatives yet, let alone distinctive design principles functions applications. Herein, applications physiochemically bacteria, classify discuss breakthroughs an emphasis on methods objective different uses beyond cancer is described. The combined strategies developing vivo biotherapeutic agents based these bacterial derivatives, elucidated how they repress other also underlined. Additionally, challenges faced by translation future development directions discussed. This review expected provide overall impression enlighten more researchers.

Язык: Английский

---

Hypofractionated radiotherapy plus PD-1 antibody and SOX chemotherapy as second-line therapy in metastatic pancreatic cancer: a single-arm, phase II clinical trial

Cancer Immunology Immunotherapy, Год журнала: 2024, Номер 73(10)

Опубликована: Авг. 6, 2024

To assess the efficacy and safety of concurrent hypofractionated radiotherapy plus anti-PD-1 antibody SOX chemotherapy in treatment metastatic pancreatic cancer (mPC) after failure first-line chemotherapy.

Язык: Английский

---

Durable response to third-line combination therapy in a metastatic colorectal cancer patient with BRAF V600E mutation: A case report

Human Vaccines & Immunotherapeutics, Год журнала: 2025, Номер 21(1)

Опубликована: Фев. 25, 2025

In metastatic colorectal cancer (mCRC), the BRAFV600E mutation subtype is one of subtypes with worst prognosis. The long-term abnormal activation multiple signaling pathways caused by BRAF V600E closely related to formation inhibitor resistance and drug-resistant tumor cell subpopulations. These factors significantly impact survival prognosis CRC patients. Therefore, treating mCRC patients mutation, particularly in later stages, challenging. We reported a case an patient primary tumors. After failure second-line treatment, this received combination therapy including immunotherapy (tislelizumab), radiotherapy, targeted (fruquintinib). Through comprehensive imaging evaluations continuous monitoring markers, we were astonished observe that has achieved maintained complete response (CR) for over 12 months. This supports efficacy mutation.

Язык: Английский

---

Moving from the background towards the spotlight: A critical review of radiation therapy for locally advanced pancreas cancer

International Journal of Radiation Oncology*Biology*Physics, Год журнала: 2025, Номер unknown

Опубликована: Март 1, 2025

Язык: Английский

---

Pancreatic Cancer: Pathogenesis and Clinical Studies

MedComm, Год журнала: 2025, Номер 6(4)

Опубликована: Апрель 1, 2025

ABSTRACT Pancreatic cancer (PC) is a highly lethal malignancy, with pancreatic ductal adenocarcinoma (PDAC) being the most common and aggressive subtype, characterized by late diagnosis, progression, resistance to conventional therapies. Despite advances in understanding its pathogenesis, including identification of genetic mutations (e.g., KRAS, TP53, CDKN2A, SMAD4) dysregulated signaling pathways KRAS–MAPK, PI3K–AKT, TGF‐β pathways), effective therapeutic strategies remain limited. Current treatment modalities chemotherapy, targeted therapy, immunotherapy, radiotherapy, emerging therapies such as antibody–drug conjugates (ADCs), chimeric antigen receptor T (CAR‐T) cells, oncolytic viruses (OVs), vaccines, bispecific antibodies (BsAbs), face significant challenges. This review comprehensively summarizes these approaches, emphasizing their mechanisms, limitations, potential solutions, overcome bottlenecks. By integrating recent advancements outlining critical challenges, this aims provide insights into future directions guide development more for PC, specific focus on PDAC. Our work underscores urgency addressing unmet needs PDAC therapy highlights promising areas innovation field.

Язык: Английский

---